GlassScriptPhysician profile
William C Hoover
NPI 1689602062
$1,001.38
in general payments reported to CMS, 2019-2025
22 companies · $83.96 in 2025
The $83.96 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $153 · 2021: $273 · 2022: $22.24 · 2023: $70.72 · 2024: $69.22 · 2025: $83.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $184.02 | 2019-2021 | |
| Abbvie INC. | $151.00 | 2021 | |
| Glaxosmithkline, LLC. | $82.46 | 2019-2023 | Arexvy |
| Abbott Laboratories | $79.73 | 2022-2024 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $65.48 | 2025 | Dupixent |
| Lilly USA, LLC | $52.72 | 2019-2021 | |
| Novo Nordisk INC | $50.22 | 2019-2020 | |
| Amarin Pharma, INC. | $41.67 | 2019-2020 | |
| Corcept Therapeutics | $37.19 | 2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $35.80 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.94 | 2019 | |
| Merck Sharp & Dohme LLC | $26.77 | 2020-2021 | |
| Allergan, INC. | $22.24 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.77 | 2021 | |
| Exact Sciences Corporation | $18.48 | 2025 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17.89 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.81 | 2019 | |
| Esperion Therapeutics, INC. | $17.74 | 2021 | |
| Electromed, INC. | $14.66 | 2024 | Smartvest |
| Supernus Pharmaceuticals, INC. | $14.15 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.52 | 2019 | |
| Pfizer INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hoover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.